COMMUNIQUÉS West-GlobeNewswire

FSR Announces $400,000 Investment in New Round of Cardiac and Pilot Grant Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis
21/01/2026
CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at Chicago, Dr. Chieh [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges [...]
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
21/01/2026
– No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE [...]
Restore Brain Announces Expansion of Neuromodulation Footprint with New St. Louis Office, Bringing Advanced TMS and SPRAVATO Treatments to the Region
21/01/2026
Dallas-based Restore Brain expands in Missouri, celebrating one year of advanced psychiatric care with innovative TMS and SPRAVATO® treatments Restore Brain Logo ST. LOUIS, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Restore [...]
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
21/01/2026
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management [...]
Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)
21/01/2026
The Phase 1 clinical study of FAP-Exd (AVA6103) is anticipated to begin later in Q1 2026 LONDON and PHILADELPHIA, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical [...]
Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
21/01/2026
MELBOURNE, Australia and SAN FRANCISCO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying [...]
InnovAge to Announce Fiscal Second Quarter 2026 Financial Results and Host Conference Call Tuesday, February 3, 2026
21/01/2026
DENVER, Jan. 21, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, and predominantly dual-eligible [...]
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook
21/01/2026
Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19 th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral [...]
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
21/01/2026
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan. 21, 2026 (GLOBE [...]
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates
21/01/2026
Interim analyses on track for the first and second half of 2026 SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused [...]
BrainsWay Announces Draft Coverage Policy from Highmark® for Accelerated Deep TMS™
21/01/2026
New draft policy from Highmark Blue Cross Blue Shield extends to both adolescent and adult depression patients BURLINGTON, Mass. and JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY [...]
NIVF Appoints Award-Winning Web3 Leader Joshua Chu to Spearhead Tokenization Strategy and Formally Engages Evident Capital to Launch Up to USD 30 Million in Tokenized Bonds by Q1, Outlining 2026 Value Catalysts
21/01/2026
BANGKOK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and [...]
Acacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
21/01/2026
ROCKAWAY, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced that Acacia Clinics and the Vagus Nerve Society [...]
Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC
21/01/2026
TORONTO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) announced today its voluntarily decision to delist its common stock from the NASDAQ Capital Market (“Nasdaq”) and [...]
PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device
21/01/2026
MINNEAPOLIS, MN, Jan. 21, 2026 (GLOBE NEWSWIRE) -- PetVivo Animal Health, Inc., in cooperation with its parent PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and affiliate PetVivo AI, Inc., an emerging biomedical [...]
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions
21/01/2026
Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects Nearly 8 in 10 adults and parents [...]
ENvue Medical Appoints Industry Veteran Marc Waldman as Vice President, Commercial
21/01/2026
Marc Waldman brings over 35 years of commercial leadership experience in the medical device industry with a proven track record of driving top-line growth TYLER, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, [...]
American Heart Association and Centre for Neuro Skills Deepen Relationship to Advance Stroke and Brain Injury Care
21/01/2026
Multi-year Sponsorship Expands Across Texas and California with Educational Resources, Community Leadership and Patient Support BAKERSFIELD, Calif. and AUSTIN, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Centre for Neuro [...]

Pages